In-depth analytical essays, capital allocation reports, clinical pipeline evaluations, and data-driven insights into the biopharmaceutical industry.
FDA approvals for Moderna's mRNA flu vaccine and Replimune's melanoma therapy headline today's harvest. IPO momentum continues (Attovia $289M, Braveheart $382M), while Supernus-Indivior and Tarsus-Alkeus deals, BioMarin's phase 3 miss, and an Alnylam earnings plunge round out a busy session.
Nineteen fresh items across 8 sources: Moderna's mRNA flu vaccine wins FDA approval, Braveheart and Tarsus make big market moves, LifeMine raises $263M, Emergent restructures, and the FDA approves the first full-spectrum narcolepsy Type 1 treatment.
A daily synthesis of the 133 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-06. Iovance Biotherapeutics +43.09% on a blowout Amtagvi-driven Q2 beat, Ensysce Biosciences +44.83% on closing its Cy Biopharma acquisition with fresh financing, and Sight Sciences +27.75% on raised guidance led the winners; BillionToOne -38.89% sold the news on a beat-without-a-raise, Emergent BioSolutions -29.58% on a NARCAN impairment and guidance cut, and Context Therapeutics -27.27% on a widening loss and Nasdaq bid-price notice. 309 names up, 258 down, median +0.32%.
A data-driven analysis of 2,912 active life-sciences job postings indexed in July 2026 across 88 companies — top hirers, in-demand roles, tech-stack keywords, geographic spread, and what the hiring data tells us about the state of biotech and pharma employment in mid-2026.
Big pharma Q2 earnings dominate (Lilly's $23B beat, Novo's pipeline setbacks, Gilead's diversification push), Amgen trims an early obesity program, Supernus and Indivior agree to merge, the FDA approves Mucinex's first OTC cold-and-flu innovation in 14 years, and AI keeps moving into clinical development.
A daily synthesis of the 90 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-05. Citius Pharmaceuticals +25.45% on subsidiary LYMPHIR commercial momentum, Bluejay Diagnostics +24.00% on SYMON-II enrollment completion, and Geron +21.64% on a Q2 revenue beat led the winners; Autonomix Medical -37.95% reversed its squeeze on dilution mechanics, Vivos -26.31% on financing terms, and Jupiter Neurosciences -25.68% on a 1-for-75 reverse split. 309 names up, 256 down, median +0.24%. The full report is at the bottom.
Sixteen fresh items across five sources today: Pfizer axes an ex-Metsera obesity asset, Merck logs a mid-stage win and miss from its Prometheus bet, KKR inks a $5.7B take-private of Integer, Latigo sets $247M IPO terms, Lisata cuts 72% of staff, and the Congo Ebola outbreak passes 1,700 deaths.
A daily synthesis of the 170 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-04. Autonomix Medical +434.25% on a patent-catalyst low-float squeeze, Adagio Medical +73.91% on day two of the FDA Expanded Access milestone, and Bruker -21.79% on a Q2 revenue miss with soft FY2026 guidance. 434 names up, 137 down, median +2.41%. The full report is at the bottom.
Supernus-Indivior $2.2B CNS merger, AZ-BMS merger talks per FT, Curium's ~$8B Lantheus buy, Lilly-Resilience $750M device investment, BlossomHill and Apnimed IPOs, Amgen cloud breach, and Novo's Phase 3 IL-6 setback headline the day.
A daily synthesis of the 113 anomaly-flagged stock moves across the 581 public biotech and life-sciences companies we track on 2026-08-03. Lunai Bioworks rose 23.20% on the naked-short-selling litigation narrative, Adagio Medical jumped 21.60% after the first patient was treated with its vCLAS Ultra ablation system under FDA Expanded Access, and MIRA Pharmaceuticals fell 22.49% as a Nasdaq delisting notice reset the tape.
Seven Endpoints News items covering Novo Nordisk's late-stage cardiovascular failure, AbbVie's Skyrizi-driven guidance raise, Moderna's norovirus readout delay, Alnylam's Q2 slump, the 340B rebate pilot, and pharma tariff timing.
48 articles from 7 sources covering FDA regulatory activity, corporate earnings, deal activity, and policy developments in biopharma.
Today's biopharma news cycle spans Apnimed's $192M IPO, Alnylam's full-year guidance cut, Replimune and Capricor adcomm fallout, Sanofi's pipeline concerns after weak Dupixent-dependent earnings, plus the FDA's first freeze-dried plasma product license. Sixty articles across ten sources.
A daily synthesis of the 108 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-31. Karyopharm collapsed 72.61% on the XPORT-EC-042 Phase 3 failure, BioAge fell 63.62% in sympathy with Novo Nordisk's failed ZEUS NLRP3 readout, and Nuwellis -60.90% gave back Thursday's pediatric cardiorenal pop after a $3.4M registered direct offering.
44 fresh articles harvested across BioSpace, Endpoints, STAT and FDA Newsroom on 2026-07-30. Top clusters: Capricor/Replimune FDA adcomms (2 rejections), J&J-Sail $2.58B CAR-T option, Sanofi €1B write-off + new CEO R&D reset, AtaiBeckley pre-Lilly $2.8B deal context, and a wave of Q2 earnings across BMS/Regeneron/UCB/Ipsen.
A daily synthesis of the 168 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-30. Nuwellis closed +135.45% on 24.6x volume on a pediatric cardiorenal data print, Bausch Health and Corcept Therapeutics gained ~28% on Q2 beats with raised guidance, while Inovio, Capricor, and Alnylam lost 28-37% on dilution, FDA-adcom overhang, and a Q2 miss.
Forty-three fresh articles from eleven sources on 2026-07-29, with Q2 earnings (Biogen, Leqembi), FDA actions (Replimune staff review, Hengrui citations, generic weight-loss guidance, Viatris contraceptive approval), and a fresh round of reverse-merger listings. Notable: J&J $5.5B talc proposal, Eli Lilly tops productivity ranking, Vertex pays AbCellera $28M for autoimmune TCE.
A daily synthesis of the 102 anomaly-flagged stock moves across the 582 public biotech and life-sciences companies we track on 2026-07-29. Autonomix Medical rose 66.18% on 20.17x volume, while Moleculin, Silexion, and Processa fell 33%–38% on financing and sell-the-news pressure.
GSK's £2.5B three-year cost-saving plan dominated the trade-press conversation with five convergent headlines spanning mature-product targeting, R&D consolidation, and a £1.33B cough-trial write-down; Altimmune's GLP-1/GIP dual scored an 'unequivocal' Phase 2 in heavy drinking, opening the alcohol-use-disorder lane; Novo Holdings-backed Claris Bio and RA Capital-launched Oak Hill Bio each closed their debut rounds on the same morning; the FDA's July adcomm slate — Replimune, Capricor, six wellness peptides — previewed a busy late-summer advisory committee cycle; Outlook Therapeutics finally won FDA approval of Lytenava after three prior CRLs.
A daily synthesis of 91 anomaly-flagged moves across 582 public biotech and life-sciences companies. OPK surged on a Q2 beat, NAUT fell on a broadscale-kit timeline reset, and a defensive healthcare bid outpaced small-cap biotech.
AstraZeneca led the day with three convergent signals — solid Q2, ADC pipeline discipline, and an AI-led late-stage trial strategy; Sarepta and Legend Biotech both announced abrupt CEO transitions; Argenx paid $2.2B for Forte Biosciences and its Phase 2 vitiligo candidate; the FDA recommitted to advisory committees while Dexcom became the first to join a new FDA/CMS health-tech pilot.
A daily synthesis of the 86 anomaly-flagged stock moves across the 583 public biotech and life-sciences companies we track on 2026-07-27. ENTX +91.22% on 15.66x volume on a $275M BVF-led oversubscribed private placement, FBRX +39.65% on 11.89x volume on argenx's $2.2B acquisition announcement at an 86% premium, GOSS +46.62% on 11.55x volume on reacquisition of worldwide seralutinib rights ahead of a September 2026 NDA submission, MPLT -72.91% on 9.21x volume on a Phase 2 ZEPHYR once-daily dosing-arm failure, CAPR -64.49% on 10.52x volume on an FDA briefing-materials negative read ahead of the July 29 AdCom, and PFSA -28.65% on 12.18x volume on a dilutive acquisition-financing 8-K. The cross-cutting pattern was a 1.64-to-1 advancer ratio at the 583-name aggregate (351 up vs 214 down) with median +0.79% / mean +0.61% / stdev 7.47%, SPY +0.02%, XBI +0.07%, IBB +0.10%, XLV +0.51% with defensive healthcare outperforming broad biotech by 0.44 points, and Devices — Surgical +2.56% as the leading sector bucket above 5 companies.
Today's harvest from BioSpace, Fierce Pharma, Fierce Biotech, and STAT News surfaces two Amgen stories (FDA appeal for Tavneos, ~40 layoffs) plus a Roche Q2 pipeline update from CEO Schinecker and a Fierce Biotech study flagging genetic risk markers in Yescarta patients.
Nineteen articles from 9 sources harvested between 2026-06-25 and 2026-07-25. Coverage clusters around FDA advisory panels (peptide compounding, Amgen's Tavneos defense), major oncology approvals (GSK's $10.6B bet), the Novo-Lilly ad-suit escalation, and Venus Medtech's trilingual TAVR enrollment milestone. The week's biggest missing beat: no AI-bio clinical readouts.
A daily synthesis of the 63 biopharma news items the OpenBio News harvest cron pulled this morning: Trump's renewed tariff threat on generic drugs not made in the US, FDA adcomm voting in favor of lifting restrictions on BPC-157, Scribe Therapeutics' $129M IPO, Lundbeck's Fast Track for an orexin-2 narcolepsy drug, Roche's FDA clearance for cobas BV/CV, FDA leadership transitions under the new commissioner, Repligen's $1.5B BioLife buy, and 18 newly-tagged mid-cap companies.
A daily synthesis of the 93 anomaly-flagged stock moves across the 584 public biotech and life-sciences companies we track on 2026-07-24. ADVB +13.11% extended its post-IPO momentum on confirmation the $25M Helena Global equity line was terminated without any shares being issued, GDTC +12.50% traded on a 24.99x volume ratio on the back of disclosed insider buying, and ZVRA -23.92% was crushed on a negative CHMP opinion from the European Medicines Agency's expert panel on arimoclomol for Niemann-Pick disease type C. LSTA -21.23% collapsed on the formal termination of the Kuva Labs merger after the buyer failed to secure financing. HOWL +18.55% and JUNS -20.92% were the two prior-cycle continuations. The cross-cutting pattern was a 0.41-to-1 advancer ratio at the 584-name aggregate (165 up vs 406 down) with median -1.56% / mean -1.80% / stdev 3.86%, XBI -1.15% underperforming SPY +0.10% by 1.25 points, XLV +0.70% the only positive sector benchmark, and Devices – Surgical +0.25% as the only positive sector bucket above 5 companies.
A daily synthesis of the 26 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Jideytro (zidesamtinib) for ROS1-positive NSCLC validating GSK's $10.6B Nuvalent acquisition, Lilly's triple-G agonist hitting 22% weight loss in Phase 3, J&J's bispecific combination delivering 89% PFS in multiple myeloma, Roche's late-stage pipeline confidence, Sanofi FDA untitled letter over Beyfortus, FDA TEMPO digital health pilot selection, Scancell/Neuphoria reverse merger, BeOne's $300M U.S. manufacturing expansion, and a Merck Ebola vaccine trial in the DRC.
A daily synthesis of the 74 anomaly-flagged stock moves across 584 public biotech and life-sciences companies. Neuphoria's merger, Advanced Biomed's post-IPO momentum, and a defensive healthcare rotation defined the session.
Today's 49-article harvest covers Merck's oral PCSK9 launch, Lilly's $2.8B AtaiBeckley deal, Agios's sickle cell disappointment, FDA's PreCheck manufacturing pilot, and AstraZeneca's Wainua flop.
A daily synthesis of the 86 anomaly-flagged stock moves across the 584 public biotech and life-sciences companies we track on 2026-07-22. ADVB +73.02% on 9.13x volume led the upside as the Advanced Biomed $6.56M IPO closed at $7.08 and the simultaneous termination of the $25M Helena Global equity line removed a 2.1x-equity-base dilution overhang; ARWR +19.03% on 2.41x volume extended on positive Phase 3 top-line results from lead RNA-interference candidate plozasiran in cardiometabolic indications; MSLE +14.72% continued last week's TRAILHEAD momentum on no fresh catalyst. On the downside, TRIB -15.44% sold the news on the announcement of a 1-for-30 reverse ADS split effective 7/24 intended to regain Nasdaq compliance, TRAW -10.60% extended a -17.1% five-day dilution-overhang slide on a July 1 registration statement, ZNTL -10.18% drifted on pre-ESMO 2026 positioning with no same-day catalyst. The cross-cutting pattern was a 0.37-to-1 advancer ratio at the 562-name aggregate (151 up vs 411 down) with median -1.67% / mean -1.37% / stdev 4.67%, XBI -1.55% lagging SPY -0.12% by 1.43 points and IBB -1.22% / XLV -0.51%, and Diagnostics +1.23% average as the only positive sector bucket.
Today's harvest (32 new news files + 6 new company JSONs) covers five threads that stood out: Gilead + Merck's Phase 3 data backing a first weekly oral HIV pill, Agios dropping its next-gen sickle cell candidate, Samsung Biologics' $1.8B PolyPeptide buyout, a wave of US-biotech Hong Kong IPOs (Axiom), and the Novo-Lilly GLP-1 ad fight. FDA activity ran hot: 14 new CRLs released, a third rejection for Hengrui-Elevar's liver cancer combo, and the FDA's radical-transparency policy running into legal uncertainty. Smaller beats: Novartis geography-agnostic on China deals, Moderna-CureVac patent litigation, Scholar Rock's apitegromab site-classification wait, and Tempus AI's $1.5B Personalis buy. Tier 1 cron additions: jupiter-neurosciences, scholar-rock, legend-biotech, agios-pharmaceuticals, samsung-biologics, tempus-ai. STAT News and BioSpace both ran opinion pieces that the political-filter dropped at parse time.
A daily synthesis of the 107 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-21. LSTA -36.45% on 9.24x volume led the downside as the $7.00 Kuva Labs tender offer hit its extended 7/21 outside date with deal-closing risk priced in; ADVB -20.45% sold the news on the effective date of the Helena Global equity-line termination; ERNA -16.39% extended a -25.1% five-day slide on a routine 8-K investor-deck refresh. On the upside, FEMY +19.57% on 4.71x volume, TELO +17.49% on a 2.05x prior-day-bounce off Monday's -17% selloff, and PVLA +15.94% on a half-recovery off Friday's 21% drop. The cross-cutting pattern was an XBI +2.36% broad-sector rally where the 585-name aggregate printed median +1.63% / mean +1.59% / stdev 4.22%, 412 advancers vs 158 decliners, and 5 of the 6 top movers were Class 1 or Class 5 (mechanical / prior-cycle / no fresh catalyst) — only LSTA carried a real same-week catalyst, going the wrong direction on a buyout-in-jeopardy. Sector leader: Nanotechnology +8.34% across 3 names, with broader leadership from Devices - Imaging +4.20% (8 names) and AI/ML +3.85% (6 names).
Today's recovered batch (46 new news files, recovered from the 9 AM PT cron that aborted mid-write) covers three threads that stood out: Eli Lilly's $3.8B psychedelics move via AtaiBeckley, Samsung Biologics' $1.8B all-cash bid for PolyPeptide, and two parallel AI-supercomputer announcements (BMS with Nvidia, BMS-Nvidia separate coverage). Other themes: Novo's oral Wegovy cleared in the EU, Merck's oral PCSK9 (enlicitide) becoming the first oral option in the cholesterol-lowering PCSK9 class, German lawmakers' cost-savings bill that drugmakers warn will drive R&D out, FDA's CRL-release pause, the EU's Sanofi flu-vaccine antitrust probe, FDA's psychedelic-guidance finalization, and Camurus's CAM2029 NDA resubmission acceptance. Endpoints News contributed the largest share (15 articles) but with notable paywall filtering; STAT News's editorial surface ran warm on political/healthcare-policy commentary that the cron filtered at parse time per Rule 7.
A daily synthesis of the 104 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-20. ADVB +76.94% on 25.39x volume led the upside on the close of a $6.56M IPO that retook Nasdaq listing compliance; ONCO +31.54% on the round-$1.00 psychological level after two 2026 reverse splits; PFSA +12.72% on a post-reverse-split drift bounce. KPTI -21.45% on 4.19x volume led the downside on the July 17 retention-PSU program; PVLA -21.04% on sell-the-news continuation off the July 14 corporate presentation; CTOR -17.26% on dilution overhang from the May 15 Q2 results. The cross-cutting pattern was a mechanical-and-prior-cycle tape: 5 of the 6 top movers were Class 1 or Class 5 (no clean fresh catalyst), only ADVB and KPTI carried primary-source catalysts dated within the prior week, and the broad tape underperformed — SPY -0.16%, XBI -2.15%, IBB -1.70%, XLV -1.14%, with 430 decliners vs 142 advancers and 19 of 20 sector categories finishing negative. Sector leader: Devices - Imaging +1.62% across 8 names.
Today's harvest (8 new news files + 1 new company JSON) is unusually thin on the heavy trade-press beats — Endpoints News contributed 16 candidates but every URL was gated by its soft paywall, and STAT News's editorial surface ran warm on politically charged healthcare items that the cron filtered out at parse time. The day's write-eligible set clusters on three narrower threads: a topical skin-closure product launch from BRIJ Medical (BRIJ-SEAL™), a small set of federal-healthcare / professional-society items (APhA's FDA comments on peptide substances, Presage's FedRAMP authorization via Kno2, Salus Scientific's burn-care consensus welcome), and two device-business items (Poriferous's DuraBloc patent, ANF Care's US wearable launch). One STAT international public-health story (WHO pressing Uganda on Marburg updates) and one borderline healthcare-policy item (Medicare smoking-cessation coverage expansion) round out the day.
Today's harvest (10 articles) clusters around three themes: a continued biotech IPO wave with Braveheart, Attovia, Vogenx, and BlossomHill pricing deals; the FDA's approval of the first oral PCSK9 inhibitor (Merck's Lipfendra / enlicitide) and the full approval of Novartis's Fabhalta in IgAN; and a pair of late-stage M&A developments — the Jasper Therapeutics all-stock merger with Kira Pharmaceuticals, and Eli Lilly's $2.8B acquisition of AtaiBeckley. Endpoints News contributed 20 candidates but every URL is gated by Endpoints' soft paywall; political/healthcare-policy items (transgender care, CDC confirmation, vaccine injury claims, China biotech restrictions, CMS GLOBE/GUARD litigation) were filtered at parse time.
GSK culls a $2B Bellus chronic-cough drug after Phase 3 failure; Celcuity's Revtorpyk wins FDA breast cancer approval; biotech IPO filings accelerate (Braveheart, Attovia, BlossomHill) and M&A stays heavy with Lilly's $2.8B AtaiBeckley psychedelics buyout and Dimerix's $292M Mission kidney deal.
A daily synthesis of the 101 anomaly-flagged stock moves across the 585 public biotech and life-sciences companies we track on 2026-07-17. XNCR +16.86%, JSPR +14.34%, and ETON +13.79% led the upside on a clean ESMO 2026 oral-presentation slot (XmAb819 in ccRCC), the closed Jasper/Kira all-stock merger plus $132M PIPE, and a Canaccord $60 price target on Eton respectively. BRNS -17.09%, GLSI -14.15%, and ISRG -14.15% led the downside — a tape dominated by Intuitive Surgical's Q2 earnings beat-but-no-raise (the day's defining feature), a sell-the-news continuation off GLSI's prior-day FLAMINGO-01 European approval, and a no-clean-catalyst thin-trade sell-off in Barinthus Bio. The cross-cutting pattern was a bellwether-led session: SPY -1.54%, XBI -3.00%, IBB -1.20%, XLV +0.16% — the broad market closed modestly red while biotech ETFs underperformed by 1.46 to 1.80 percentage points, dragged by ISRG's worst day since April 2022 even as 271 of 585 small/mid-cap names finished green (mean +0.11%, median -0.21%, stdev 4.11%). Sector leader: Antibodies +2.09% (n=40).
A daily synthesis of the 39 biopharma news items the OpenBio News harvest cron pulled this morning: FDA approval of Merck's oral PCSK9 inhibitor Lipfendra, two parallel Lilly psychedelic buyouts (AtaiBeckley, ~$2.8-3.8B), projected 14,000+ H1 biopharma layoffs, Sanofi's mRNA-patent suit against Pfizer and Moderna, an FDA screwworm-drug EUA, and the Vogenx and Braveheart IPO filings.
A daily synthesis of the 137 anomaly-flagged stock moves across the 580 public biotech and life-sciences companies we tracked on 2026-07-16. ATAI +33.40% on Eli Lilly's announced $3.8B acquisition (cash + CVR), CDNA +35.60% on Naveris close + $171.2M Lab Products sale to Eurobio, and JSPR +11.85% on an all-stock Kira merger plus concurrent $132M PIPE led the upside. On the other rail, SNTI -21.19% printed a second-day continuation of yesterday's Celadon-led NewCo spin-off, while MODD -22.67% and KALA -17.76% continued to bleed on prior-month reverse-split + ATM / shelf overhang (the report's prior-cycle catalyst rule applies to all three losers). The cross-cutting pattern was a two-rail day: three discrete M&A prints lifted the advancer side while the loser side was entirely continuation-driven with no fresh primary-source catalysts dated July 16. Sector leader: Psychedelics & Related +6.10% (n=5) on ATAI deal flow.
45 news items harvested from 11 biopharma outlets, covering Kelun-Merck's NSCLC ADC win, biotech IPO momentum, Celcuity's breast-cancer approval, FDA CRL policy resumption, and Bora-Insilico's $2.5B AI partnership.
A daily synthesis of the 87 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-15. IOVA +20.61%, BEAT +17.71%, and RCEL +17.66% led the upside on continuation reads, while SNTI -39.71%, CRDF -32.11%, and QTTB -14.95% led the downside on three clean fresh dilution-print catalysts (Senti spin-off, Cardiff $10M direct, Q32 $200M public). The cross-cutting pattern was a dilution-day where SPY printed +1.26% to a fresh high but biotech ETFs diverged sharply — XBI -4.14%, IBB -3.28%, XLV -2.47% — even as 339 of our 587 small/mid-cap names finished green (mean +0.68%, median +0.58%, stdev 4.62%). Sector leader: Generic Drugs +4.17% (n=5).
Today's harvest: 37 fresh news files. Dominant themes: large-pharma dealmaking (Vertex-Crinetics, AstraZeneca-Dizal, Spero-Innovent, Avere-Hansoh, Chai Discovery $400M); the AstraZeneca-Ionis Wainua Phase 3 cardiomyopathy failure landing on three sources; FDA simplification of pharmaceutical manufacturing and registration (three separate articles); FDA approval of Leqembi Iqlik SC starter dose (Biogen/Eisai); and FDA psychedelics guidance finalization. Endpoints News was fully soft-paywalled (28/28 rejected) for the fifth consecutive run; STAT ran political/feature content the editorial filter dropped.
A daily synthesis of the 103 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-14. JSPR +18.90%, BTAI +16.75%, and GALT +16.09% led the upside on no fresh news; XAIR -22.96%, SPRO -22.02%, and NTHI -14.81% led the downside on a reverse-split distribution, a $105M royalty-financing sell-the-news reaction, and insider-distribution flow. The cross-cutting pattern was a zero-clean-catalyst day where 6 of 6 top movers were Class 1/4/5 (mechanical, strategic, prior-cycle) and zero were Class 2 (clean clinical / regulatory readout) — a structurally quiet tape where XBI +0.07% essentially matched SPY +0.36%. Sector leader: Psychedelics & Related +3.09% (n=5).
Today's harvest landed 20 fresh news files across 7 sources. The dominant theme is regulatory and deal flow: FDA posted new CRLs days after pausing the disclosure program, Boehringer's nerandomilast (Jascayd) became Europe's first new IPF drug in years, Q32 Bio's anti-IL-7R antibody bempikibart jumped on Phase 2 alopecia data, and AstraZeneca's new Sino Biopharm COPD pact surfaced via MedCity News. Endpoints News was fully soft-paywalled and contributed zero articles this run despite 13 candidates. STAT News and Reuters Biopharma contributed only filtered-out items (political, op-ed, author name, general market).
A daily synthesis of the 140 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-13. Q32 Bio (QTTB) ran +90.72% on positive 36-week topline data from Part B of SIGNAL-AA, a bempikibart Phase 2a in alopecia areata. On the downside, Cadrenal (CVKD -16.26%) sold off despite positive late-breaking Phase 2 HIT data after a 2.94M-share secondary offering by selling stockholders hit the tape the same day; Cue Biopharma (CUE -15.93%) closed a previously announced $50M private placement at $33.21; Aardvark (AARD -21.58%) gave back without fresh news as the market lost patience with the delayed Q2 FDA guidance on its ARD-101 clinical hold. The cross-cutting pattern was biotech-specific risk-off on dilution and missing-Q2 guidance, with XBI -2.32% lagging XLV +0.35% by 267bps. Sector leader: Generic Drugs +3.02% (n=5).
Today's harvest: 1 fresh news file from BioSpace covering FDA's pause on public release of Complete Response Letters following an April citizen petition. Endpoints remained fully paywalled; STAT ran several politically charged pieces and healthcare-feature columns that the editorial filter dropped; prior-run coverage of AstraZeneca/Ionis/Wainua, Roche/Huntington's, and Bausch+Lomb/glaucoma topic clusters absorbed the remaining fresh candidates.
Today's harvest: 4 fresh news files spanning an FDA approval (Padcev-Keytruda in MIBC), a balance-sheet deal (Bayer-Apollo), a BioMarin patient-marketing push for PKU teens, and a Phase 3 ADC win for the GSK-Hansoh partnership in China. Endpoints soft-paywall and topic duplicates with prior coverage held the headline count down.
Today's harvest adds 26 free biopharma items across 6 sources, led by FDA/regulatory updates, clinical-development signals, China-linked partnerships, financing and M&A coverage, and selected company leadership or manufacturing moves.
A daily synthesis of the 101 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-10. Aardvark rebounded +52.00% on 11.14x volume, Forte added +19.67% as the FB102 vitiligo readout continued to reprice, and Rapid Micro Biosystems gained +17.82% on life-sciences tools follow-through. On the downside, Profusa fell -16.54% in a post-split resale-registration cycle, Anbio Biotechnology lost -15.78% after a mixed shelf filing, and Tvardi gave back -13.68% after its early-week TTI-109 Phase 1 rally. The cross-cutting pattern was a biotech-specific risk-off tape: SPY rose +0.43%, but XBI fell -3.20%, IBB fell -2.68%, and XLV fell -0.82%.
A source-backed deep read on Insilico Medicine's Pharma.AI platform, the rentosertib Phase 2a GENESIS-IPF data published in Nature Medicine in June 2025, the HKEX:3696 listing in December 2025, the Phase 3 initiation in July 2026, and the Lilly / Servier / SK Biopharm / Takeda partnership wave that pushed headline deal value past $6.7B in seven months. Includes the per-claim audit of the marketing vs. the peer-reviewed record, and a critical read on the Phase 2a sample size, the liver-toxicity signal in nintedanib combination, and the Phase 3 protocol.
56 fresh biopharma items across 7 sources (Endpoints News was fully soft-paywalled today so 37 of its candidates were dropped). BioPharma Dive contributed 17 of the 56 items including Roche KRAS head-to-head, Alkermes CEO succession, MeiraGTx/Oberland $400M financing, and Celea $180M IPF. FDA approvals landed for ENNUMO (Accord BioPharma), Theranica Nerivio coverage, WuXi Biologics PLI approval, and Vera Therapeutics atacicept for IgAN. Alector absorbed GSK's abandoned $700M Alzheimer's collab while Fate's off-the-shelf CAR-T prospect reported early promise in systemic sclerosis.
A daily synthesis of the 97 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-09. Forte Biosciences surged +78.33% on 8.38x volume after reporting positive Phase 1b FB102 vitiligo data (29.6% mean FVASI improvement at week 24, p=0.020); TransCode Therapeutics ran +21.84% on a Nasdaq listing-conversion catalyst (Series A/B preferred-to-common); Oncolytics Biotech gained +16.12% on a delayed reaction to the July 8 auditor-change disclosure (E&Y → Baker Tilly, with going-concern explanatory paragraph from prior reports). On the downside, Ionis Pharmaceuticals fell -23.90% on 7.51x volume after the CARDIO-TTRansform Phase 3 trial for eplontersen in ATTR-CM missed its primary efficacy endpoint; Tvardi Therapeutics gave back -24.00% as the post-Phase-1 TTI-109 readout profit-taking continued; TScan Therapeutics fell -15.87% on fading Phase 3 alignment momentum. The session was a clean broad-sector rally: the S&P 500 closed +0.85%, the XBI +0.80%, the IBB +0.69%, the XLV +0.94% — broad healthcare outperformed the S&P 500 and the 5.43% StDev was the signature of marquee single-stock flow (FBRX, IONS) on an otherwise positive tape. Sector leaders: Psychedelics +3.57% (n=5), Diagnostics +2.89% (n=31), Genetics & Genomics +2.87% (n=7). Sector laggards: New England -2.61% (n=7), Stem Cells / Cellular Therapy -0.93% (n=24).
53 fresh biopharma items across 8 sources. Vertex's $10B Crinetics buy and a $400M MeiraGTx financing headline the day; FDA hands Vanda, Octapharma, and Porton Advanced multiple approval-track wins; Endpoints News is fully paywalled today so the major M&A and 340B stories landed only via Fierce Pharma and BioPharma Dive.
A daily synthesis of the 120 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-08. Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data extended Tuesday's run (TVRD +61.29% on 8.94x volume, 5d +163.2%); Elicio bounced +24.64% after closing a $15M registered stock sale to fund its KRAS cancer program; TScan Therapeutics ran +17.76% on Phase 3 alignment. On the downside, BioXcel Therapeutics fell -22.87% on 4.99x volume as the market priced in financing risk ahead of IGALMI's at-home sNDA action date (Nov 14, 2026); Context Therapeutics' onapristone extended-release data in ovarian cancer disappointed (CNTX -14.91%); Profusa gave back -14.59% as the post-split squeeze from Monday continued to fade. The session was a clean broad-sector fade: the S&P 500 closed -0.31%, the XBI -0.55%, the IBB -0.95%, the XLV -1.30% — broad healthcare underperformed the broad market for the first session in three days. Sector leaders: Psychedelics +3.24% (n=5), Genetics & Genomics +1.63% (n=7). Sector laggards: AI / Machine Learning -3.39% (n=6), Devices — Implants -3.16% (n=10).
Today's harvest surfaced 3 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Endpoints' second-half M&A kickoff led by Novartis/Vertex/Ipsen with up to $12.6B in new deals on top of a 45-deal H1 2026, BioPharma Dive's coverage of Ipsen's Memo Therapeutics buyout as a rare-disease buildout, and MedCity News's angle on Novartis's Myricx ADC differentiation thesis.
A daily synthesis of the 142 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-07. Vertex announced an all-cash $10B acquisition of Crinetics at $85/share, lifting CRNX +98.74% to a 52-week high; Tvardi's positive Phase 1 TTI-109 STAT3-inhibitor data sent TVRD +54.23% on 24x volume; Akari +42.02% on a LoRusso SAB appointment. On the downside, CollPlant called a July 29 EGM to vote on a 16.7x share-capital increase, Elicio was hit with a Pomerantz securities-fraud probe, and CapsoVision extended a multi-week slide with no fresh catalyst. The session was a clean Class-2-and-3 day: a marquee buyout, a clinical readout, a credibility hire, and a financing overhang — not mechanical.
Today's harvest across 11 biopharma news sources surfaced 8 articles after 30-day + URL-dedupe + political-deny + Tier-2 cross-site collapse. Headlines cluster around Novartis's $1.5B Myricx ADC deal, Genentech's 103-job layoff paired with a $490M Astex biobucks pact, Scribe Therapeutics' IPO signal, BridgeBio's Attruby kidney-benefit positioning, Movmedix's US FDA-cleared entry, Celea's $180M IPF pivotal funding, a 5-molecular-glue overview, and a BioSpace H1-2026 FDA retrospective.
A daily synthesis of the 110 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-06. Celularity ran +29.09% on a sub-$1 short-squeeze; Profusa jumped +21.93% on the eve of a 1-for-25 reverse split; BioXcel cratered -20.29% on the slide toward Nasdaq bid-price compliance; Aktis Oncology fell -16.37% as the radiopharm sector pulled back -5.10%. No clean single-day catalysts in the top six — all six are continuation plays or mechanical events.
Today's harvest across 11 biopharma news sources surfaced only one surviving article after filtering: a BioSpace recap of the BIO 2026 conference in San Diego noting the upbeat dealmaking and IPO sentiment, an evolving FDA posture, and a high-profile retraction of a pivotal study backing Amgen's rare-disease drug Tavneos.
Endpoints News dominates with 38 articles covering Scribe Therapeutics IPO filing, AstraZeneca's CSPC kidney drug deal, and Anthropic's Claude Science launch for pharma. Fierce Biotech contributes 10 articles including United Therapeutics' $140M thymic cell therapy acquisition and Roche's phase 3 lung cancer win.
Today's 50-article harvest clusters around four themes: FDA PreCheck pilot selections and cell/gene therapy approvals (Orca Tregzi, Vertex Casgevy pediatric label, 4DMedical TGA), M&A and licensing consolidation (Ipsen-Kartos, AbbVie-Apogee, Biogen-RayThera, AstraZeneca-CSPC, Theravance $929M buyout, Sixth Street/KKR-BridgeBio $1B), China-anchored deal flow (Pfizer-Innovent insurance, Lilly-Veropharm China, Drugmakers defend Chinese trials), and CDMO/careers signal (Lonza ADC expansion, Kimball EU/India build, 8 companies hiring in Greater Philadelphia). Notable absences: no STAT Plus pieces (paywall), zero FDA newsroom press announcements (all were older than 30 days), Endpoints coverage down to one (soft paywall) and MedCity down to three (anti-bot 403).
A daily synthesis of the 125 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Markets were closed Friday, July 3 for the observed Independence Day holiday; all prices reflect Thursday, July 2 close. Elicio down 37% on Phase 2 miss plus offering; PPCB up 23% on $5M buyback; reverse splits punished PFSA and CRIS. RNA/Gene Therapy sector led with +3.55% average move.
Today's harvest produced 46 fresh news files spanning Endpoints News, Reuters Biopharma, PRNewswire, BioSpace, and FDA Newsroom — anchored by FDA's pediatric sickle-cell gene-therapy approval, Roche's KRAS Phase 3 victory over Amgen/BMS, and BridgeBio's $1B launch fundraise, with 8 new company JSONs created.
A daily synthesis of the 125 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-02 (post-market). Elicio cratered -37.35% on a Phase 2 miss in pancreatic cancer; Profusa announced a 1-for-25 reverse split; Propanc surged +22.92% on a $5M buyback. RNA/Gene Therapy and Small-Molecule Pharma led sector averages (+3.55% and +2.23%); Devices — Imaging and Diagnostics lagged (-2.28% and -0.38%). XBI +2.50%, IBB +2.93%, XLV +2.63% — healthcare broadly bid with a sharp divergence underneath.
Today's incremental harvest produced a single new article — BeOne's Brukinsa hitting its primary endpoint in a Phase 3 mantle-cell-lymphoma confirmatory trial — while 19 of 20 candidates were already represented in the news folder, reflecting a backlog-cleanup pattern with 20-article candidates against 1 truly new piece.
A daily synthesis of the 143 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-07-01. Neuphoria cratered -18.76% on 6.84x volume after Merck terminated its partnered Alzheimer's Phase 2. Devices and Diagnostics led sector averages (+2.48% and +2.35%); small-molecule pharma, RNA/gene therapy, and psychedelics lagged. Only one of the top six movers had a clean single-name catalyst on the day — most of the tape was continuation of prior-cycle news.
FDA PreCheck Pilot Program with Lilly and Regeneron headlined a heavy regulatory day; Sobi and Unicycive received new CRLs for contract manufacturing; Viridian's Lumvoa approved to challenge Amgen's Tepezza; Zymeworks to acquire Theravance for $929M.
A data-driven analysis of 6,804 active life-sciences job postings indexed in June 2026 across 138 companies — top hirers, in-demand roles, tech-stack keywords, geographic spread, and what the hiring data tells us about the state of biotech and pharma employment in mid-2026.
Nine fresh items harvested from the four biopharma homepages on 2026-06-29, with M&A headlines (Zymeworks-Theravance, Ipsen-Kartos), a Sobi CRL on both Fierce Pharma and Endpoints, and a Viridian FDA approval / market debut dominating the cycle. Industry-volume is moderate, with FDA activity, M&A, and one clinical-failure news.
Deep analysis of the FDA's June 29, 2026 announcement of seven companies selected for the PreCheck Pilot Program — what the selection criteria actually were, who the winners are, what their facility investments look like, and what this means for each company's strategic positioning, the broader CDMO landscape, and the US biopharma supply chain.
Across our internal biotech cohort, 71 publicly-verified upcoming catalyst events sit in the database — 17 with exact PDUFA/readout dates, 51 in sponsor-stated quarters, and 3 still TBD. Today's breakdown covers Q3 2026 (17), Q4 2026 (18), and H1 2027 (12), plus the cross-cutting conference placements, the 41 H1-2026 items we deliberately crossed off the calendar, and one notable caveat (an outlook-therapeutics 4th BLA resubmission) that explains why some 'exact date' PDUFAs are actually long-shot recoveries.
Five fresh items harvested from the four biopharma homepages on 2026-06-28, with FDA approvals and a CMO warning letter dominating the cycle. Industry-volume is light post-BIO 2026 and pre-Q2 earnings season.
A daily synthesis of the 10 biopharma news items the OpenBio News harvest cron pulled this morning: FDA advisory panel scheduling for Replimune and Capricor, a Viridian eye-drug approval framed as competition with Amgen's Tepezza, a SCOTUS Roundup ruling and its two-day aftermath, the GSK new-CEO buyout, Pfizer-Seagen cooling vs. a Pfizer-Innovent China pact, a 'historic' solid-tumor CAR-T nod, and an Ebola case count crossing 1,000 in Congo.
A source-backed ranking of the AI-bio companies that actually matter in June 2026 — Isomorphic Labs, Insilico Medicine, Recursion, Valo Health, Schrödinger, Insitro, Generate, Tempus AI, Iambic, and Biolojic Design. With their pipelines, pharma deals, and the read on what separates the top 10 from the 320+ other AI-bio companies.
A source-backed ranking of the 10 biopharma stocks with the highest YTD returns through June 27, 2026, drawn from the full NASDAQ+NYSE biotech universe (1,072 names). Q32 Bio (+283%), Tango Therapeutics (+252%), Veradermics (+236%), Oruka (+221%), Enliven (+222%), Twist Bioscience (+208%), Absci (+202%), Liquidia (+149%), Dianthus (+140%), Revolution Medicines (+130%). Includes a methodology correction from an earlier version of this analysis.
A daily synthesis of the 154 anomaly-flagged stock moves across the 587 public biotech and life-sciences companies we track on 2026-06-26 (post-market, Friday). Curis up 55.98% on 178x volume. Tvardi down 36.44% on 33x volume. Sector rotation into devices, psychedelics, and implants. 154 names moved |%|>= 5%. The full report is at the bottom.
Generate Biomedicines' first AI-designed Phase 3 antibody dosed a patient, Insilico closed a $2.5B CNS partnership with SK Biopharm, Isomorphic Labs announced a $2.1B Series B, and Boltz/Protenix open-sourced AlphaFold 3. Here's where AI in drug discovery actually stands in mid-2026.
This week's life-sciences industry diff added 52 genuinely new companies. We dug into all of them — here are the ones with real funding momentum, big-name backers, or scientific bets large enough to move the field.
A daily synthesis of the 105 anomaly-flagged stock moves across the ~600 public biotech and life-sciences companies we track. Today's signal: AI-designed and psychedelic-adjacent drug-discovery platforms are being rewarded on clinical validation (ABSI +34.75%, DFTX +18.23%), while orphan-disease single-asset micro-caps are being punished on dilution (CGTX -34.33%, NUWE -33.52%). Includes a 6-class taxonomy of mover signal and the underlying catalysts for the top 6 movers.
An in-depth analysis of how leading pharmaceutical companies are restructuring their research and development budgets, focusing on clinical trial efficiency and modality prioritization.
How does the performance of computational and AI-designed molecules compare with traditional discovery pipelines in early clinical trials?
An in-depth analysis of biotechnology employment, salary trends, in-demand technical roles, and hiring strategies in 2026.
A comprehensive look at biotech IPOs in 2025 and 2026, analyzing deal sizing, post-IPO performance, and the macro-indicators driving market recovery.